NCT00095680View on ClinicalTrials.gov

Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

February 28, 2006

Conditions
Multiple Myeloma
Interventions
DRUG

SCIO-469

two 30-mg capsules three times daily

DRUG

SCIO-469 and bortezomib

The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study

All Listed Sponsors
lead

Scios, Inc.

INDUSTRY

NCT00095680 - Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter